Shigellosis, commonly known as bacillary dysentery, is a gastrointestinal infection caused by Shigella bacteria. These bacteria spread via the fecal-oral route and only a small inoculum can cause disease. The four Shigella species that cause disease in humans are S. dysenteriae, S. flexneri, S. boydii, and S. sonnei. Globally, there are an estimated 99 million cases and over a million deaths due to shigellosis annually, with a majority of deaths occurring in developing countries and among young children. While mortality from shigellosis has decreased over time, it continues to place a significant disease burden, especially in areas with poor sanitation and hygiene conditions.
Current Prevention and Treatment Options
Current prevention strategies focus on improving water, sanitation and hygiene conditions to reduce transmission. Antibiotics are the mainstay of treatment, but antibiotic resistance is a major concern, limiting treatment options. Multidrug resistant strains are increasingly common worldwide. Moreover, antibiotics only lessen duration and severity of symptoms and do not prevent transmission or long term carriage. As environmental and hygiene measures alone cannot completely control transmission, there is a pressing need for an effective Shigella vaccine.
Challenges in Vaccine Development
Development of a broadly effective Shigella vaccine has proven quite challenging. Reasons include the presence of multiple serotypes, requirement of mucosal immunity for protection and antigenic diversity even within serotypes. Most early vaccine candidates provided only partial and serotype-specific protection. More recent approaches have focused on conserved protein antigens or attenuation of live strains, but these vaccines also show limitations. The constantly evolving epidemiology of Shigella serotypes also impacts which serotypes a vaccine needs to provide protection against. Safety is another concern for live oral vaccines in young children and individuals with compromised immunity.
Progress So Far
Despite challenges, some vaccine candidates have shown promise in clinical trials. An oral, live attenuated S. sonnei vaccine tested in young children demonstrated good safety and efficacy profiles. A tetravalent (provides protection against four serotypes) glycoconjugate vaccine developed by the National Institutes of Health showed 60-80% protective efficacy against homologous serotypes in phase 2 clinical trials. This vaccine is based on the O-specific polysaccharide of each serotype conjugated to a carrier protein. Conjugation enhances the immunogenicity of polysaccharides. A live attenuated tetravalent vaccine is also under development but more data on safety and efficacy is awaited. While progress has been made, further evaluation is still required before a broadly effective Shigella vaccine can be recommended for use.
Gaps Limiting Vaccine Introduction
There are still a few gaps limiting the introduction and widespread use of a Shigella vaccine. The currently available candidates have shown variable levels of protection against different serotypes. Improving the breadth and magnitude of the immune response to provide cross-protection remains a challenge. Other limitations relate to the diversity of serotypes found in different geographic regions. Local epidemiological data and evidence of impact in endemic areas will be important to assess which serotypes a vaccine should include. As shigellosis occurs largely in developing countries, feasibility and cost-effectiveness of a vaccine also need to be established for use in resource-poor settings. Finally, immunological correlates of protection are not well defined, making it difficult to predict vaccine efficacy based on laboratory assays. Continued research efforts are required to address these gaps and accelerate Shigella vaccine development and introduction.
Concluding Remarks
In summary, Shigella infections impose a significant disease burden globally, predominantly among young children in the developing world. Environmental interventions alone are not sufficient to curb transmission. While antibiotics can treat clinical cases, they do not prevent spread. An effective Shigella vaccine holds great potential for reducing illness and spread. Significant progress has been made in developing vaccine candidates, but further evidence of safety, efficacy and effectiveness in endemic areas is still awaited. Addressing remaining challenges related to serotype breadth, evaluation in endemic populations and cost-effectiveness will be critical to make a Shigella vaccine a public health reality to control this highly infectious disease of global health importance. Continued multidisciplinary efforts are warranted to accelerate the development of a broadly protective Shigella vaccine.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
